The field of the application relates to medical devices and procedures for treating pancreatic cancer.
Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. The National Cancer Institute estimates that there were 43,920 new cases of pancreatic cancer and 37,390 patients died from the disease in 2012. Different types of treatments are available to patients with pancreatic cancer. While surgery is generally considered the best hope for cure of this disease, only 10 to 20% of patients with pancreatic cancer are surgical candidates. Radiation therapy and chemotherapy are two other common methods to treat pancreatic cancer. However, the particular biochemical and physiologic characteristics of pancreatic cancer appear to limit the effectiveness of these standard forms of therapy. Applicant of the subject application determines that it may be desirable to have a new device and method that provide minimally invasive form of treatment of cancer to the pancreas without the undesirable side effects of chemotherapy and radiation.
A method of treating pancreatic cancer includes: inserting a device into a stomach or a duodenum; securing at least a portion of the device in position relative to the stomach or the duodenum; and delivering ultrasonic energy from the device to treat a target site in a pancreas.
Optionally, the ultrasonic energy is delivered through a wall of the stomach or through a wall of the duodenum.
Optionally, the method further includes: inserting a transducer through a wall of the stomach or through a wall of the duodenum into the pancreas; wherein the ultrasonic energy is delivered from within the pancreas to reach the target site in the pancreas.
Optionally, the at least a portion of the device comprises an anchor, and the act of securing the at least a portion of the device comprises engaging the anchor with the stomach or the duodenum.
Optionally, the anchor comprises an expandable member, and the act of engaging the anchor comprises expanding the expandable member.
Optionally, the expandable member comprises a balloon.
Optionally, the ultrasonic energy is delivered through the balloon.
Optionally, the device further comprises an additional balloon, wherein the ultrasonic energy is delivered through the additional balloon.
Optionally, the device comprises a first elongated member with a lumen, and a second elongated member disposed within the lumen of the first elongated member, the second elongated member comprising an energy source, and wherein the method further comprises moving the second elongated member relative to the first elongated member.
Optionally, the act of moving the second elongated member comprises translating the second elongated member relative to the first elongated member, rotating the second elongated member relative to the first elongated member, or both.
Optionally, the ultrasonic energy is delivered from the device to create heat, hyperthermia, or thermal ablation, at the target site.
Optionally, the ultrasonic energy is delivered to release or deliver a drug to the target site in the pancreas.
Optionally, the ultrasonic energy is delivered to create mechanical perturbations at the target site in the pancreas.
Optionally, the device comprises a plurality of energy delivery components that are spaced apart from each other, and wherein the act of delivering the ultrasonic energy comprises selectively activating one or more of the plurality of energy delivery components.
Optionally, the energy delivery components are spaced apart from each other along a longitudinal axis of the device.
Optionally, the energy delivery components are spaced apart from each other along a circumference of the device.
Optionally, the method further comprises monitoring a thermal therapy process for the target site using a sensor that senses a characteristic of the target site.
A method of treating pancreatic cancer includes: inserting a device into a stomach or a duodenum, the device having a first elongated member with a lumen, a second elongated member disposed in the lumen of the first elongated member, and an energy source at the second elongated member; securing at least a portion of the device in position relative to the stomach or the duodenum; changing a relative position between the first elongated member and the second elongated member; and delivering ultrasonic energy from the energy source of the device to treat a target site in a pancreas.
Optionally, the ultrasonic energy is delivered through a wall of the stomach or through a wall of the duodenum.
Optionally, the method further includes: inserting the energy source through a wall of the stomach or through a wall of the duodenum into the pancreas; wherein the ultrasonic energy is delivered from within the pancreas to reach the target site in the pancreas.
Optionally, the at least a portion of the device comprises an anchor, and the act of securing the at least a portion of the device comprises engaging the anchor with the stomach or the duodenum.
Optionally, the anchor comprises an expandable member, and the act of engaging the anchor comprises expanding the expandable member.
Optionally, the expandable member comprises a balloon.
Optionally, the ultrasonic energy is delivered through the balloon.
Optionally, the device further comprises an additional balloon, wherein the ultrasonic energy is delivered through the additional balloon.
Optionally, the act of changing the relative position comprises translating the second elongated member relative to the first elongated member, rotating the second elongated member relative to the first elongated member, or both.
Optionally, the ultrasonic energy is delivered to create heat, hyperthermia, or thermal ablation, at the target site in the pancreas.
Optionally, the ultrasonic energy is delivered to release or deliver a drug to the target site in the pancreas.
Optionally, the ultrasonic energy is delivered to create mechanical perturbations at the target site in the pancreas.
Optionally, the energy source comprises a plurality of energy delivery components that are spaced apart from each other, and wherein the act of delivering the ultrasonic energy comprises selectively activating one or more of the plurality of energy delivery components.
Optionally, the energy delivery components are spaced apart from each other along a longitudinal axis of the device.
Optionally, the energy delivery components are spaced apart from each other along a circumference of the device.
Optionally, the method further includes monitoring a thermal therapy process for the target site using thermal imaging.
An apparatus for treating pancreatic cancer includes: a first elongated member having a distal end, a proximal end, a body extending between the distal end and the proximal end, and a lumen in the body, the first elongated member being flexible and being sized for insertion into a stomach or a duodenum; a securing mechanism at the distal end of the first elongated member, the securing mechanism configured for securing a portion of the first elongated member in position relative to surrounding tissue at the stomach or the duodenum; a second elongated member disposed within the lumen of the first elongated member, wherein the second elongated member is moveable relative to the first elongated member; and a transducer assembly at the second elongated member for delivering ultrasonic energy at an energy level sufficient to treat a target area in a pancreas.
Optionally, the securing mechanism comprises an expandable member.
Optionally, the expandable member comprises a balloon.
Optionally, the expandable member comprises a structural mesh.
Optionally, the apparatus further includes a fluid source to expand the securing mechanism.
Optionally, the second elongated member is translatable, rotatable, or both translatable and rotatable, relative to the first elongated member.
Optionally, the second elongated member is translatable out of an opening at the first elongated member, and wherein the transducer assembly is configured to deliver the ultrasonic energy from within the pancreas to the target area in the pancreas.
Optionally, the apparatus further includes an expandable member for transmitting the ultrasonic energy from the transducer assembly to the target area.
Optionally, the transducer assembly comprises two or more energy delivery components arranged in series along a longitudinal axis of the second elongated member.
Optionally, the transducer assembly comprises two or more energy delivery components arranged around a longitudinal axis of the second elongated member.
Optionally, the transducer assembly comprises multiple energy delivery components arranged both along and around a longitudinal axis of the second elongated member.
Optionally, the transducer assembly comprises a plurality of energy delivery components, and the apparatus further comprises a user interface for allowing a user of the apparatus to selectively activate one or more of the energy delivery components, and/or to adjust an amount of energy being delivered by the one or more of the energy delivery components.
Optionally, the apparatus further includes a delivery tube for accommodating the first elongated member, wherein the delivery tube is moveable relative to the first elongated member.
Optionally, the apparatus further includes a steering mechanism for bending the distal end of the first elongated member.
Optionally, the transducer assembly is configured for delivering ultrasonic energy to create heat, hyperthermia, or thermal ablation, at the target area.
Optionally, the transducer assembly is configured for delivering ultrasonic energy to release or deliver a drug at the target area.
Optionally, the transducer assembly is configured for delivering ultrasonic energy to generate mechanical perturbations in the target area.
Optionally, the apparatus further includes an imaging device coupled to the first elongate member or the second elongate member.
Optionally, the imaging device comprises an ultrasound imaging device.
Optionally, the imaging device comprises a coil for MR imaging.
Optionally, the imaging device is alongside the transducer assembly, is embedded in the transducer assembly, or is located at a center of the transducer assembly.
Other and further aspects and features will be evident from reading the following detailed description of the embodiments.
The drawings illustrate the design and utility of embodiments, in which similar elements are referred to by common reference numerals. These drawings are not necessarily drawn to scale. In order to better appreciate how the above-recited and other advantages and objects are obtained, a more particular description of the embodiments will be rendered, which are illustrated in the accompanying drawings. These drawings depict only exemplary embodiments and are not therefore to be considered limiting in the scope of the claims.
Various embodiments are described hereinafter with reference to the figures. It should be noted that the figures are not drawn to scale and that elements of similar structures or functions are represented by like reference numerals throughout the figures. It should also be noted that the figures are only intended to facilitate the description of the embodiments. They are not intended as an exhaustive description of the invention or as a limitation on the scope of the invention. In addition, an illustrated embodiment needs not have all the aspects or advantages shown. An aspect or an advantage described in conjunction with a particular embodiment is not necessarily limited to that embodiment and can be practiced in any other embodiments even if not so illustrated, or if not so explicitly described.
The device 10 includes a first elongated member 20, a securing mechanism 30, a second elongated member 40, and a transducer 50. The device 10 also includes a first handle 70 coupled to the first elongated member 20, and a second handle 80 coupled to the second elongated member 40. The device 10 may be used with a thermal imaging device 90 for purpose of monitoring extent of the heating of the target tissue during a treatment procedure. In other embodiments, the thermal imaging device 90 may be a part of the device 10.
The first elongated member 20 includes a distal end 100, a proximal end 102, a body 104 extending between the distal end 100 and the proximal end 102, and a lumen 106 in the body 104. In the illustrated embodiments, the first elongated member 20 is flexible. In other embodiments, the first elongated member 20 may be rigid. Also, in the illustrated embodiments, the first elongated member 20 is sized for insertion into the stomach or duodenum. The first elongated member 20 may also have a length that allows the distal end 100 of the first elongated member 20 to reach the stomach or the duodenum through the mouth and the esophagus, while the proximal end 102 of the first elongated member 20 remains outside the patient.
In the illustrated embodiment, the securing mechanism 30 is an expandable member. For example, the expandable member 30 may be a balloon in some embodiment, or a structural mesh in other embodiment. The securing mechanism 30 may have a first configuration with a low profile for allowing the securing mechanism 30 to be inserted through a delivery tract to reach a target site, and a second configuration with an expanded profile for allowing the securing mechanism 30 to engage tissue for securing the distal end 100 of the first elongated member 20 relative to tissue at the target site (e.g., stomach, duodenum, etc.). For example, in the embodiments in which the securing mechanism 30 is an expandable balloon, the expandable balloon may have an un-inflated configuration so that the balloon assumes a low profile for delivery to the target site. When the balloon reaches the target site, the balloon may be inflated to expand to engage tissue at the target site. The expanded balloon may have a size that is sufficiently large, so that the expanded balloon can engage with, and press against, the wall of the stomach or the duodenum, thereby allowing the balloon to function as an anchor to secure the distal end 100 of the first elongated member 20 relative to the wall of the stomach or the duodenum. In order to inflate the balloon, the device 10 is configured to be coupled to a fluid source 108 which may include a pump (e.g., syringe) that has the ability to deliver fluid into the balloon and also to apply suction to remove the fluid from inside the balloon to deflate the balloon once the procedure is completed.
In the illustrated embodiments of
As shown in the figure, the first handle 70 is secured to the proximal end 102 of the first elongated member 20, and the second handle 80 is secured to the proximal end 122 of the second elongated member 40. Movement of the second elongated member 40 relative to the first elongated member 20 may be achieved by manipulating the first handle 70, the second handle 80, or both. For example, in some embodiments, the second handle 80 may be axially translated (along a longitudinal axis 130) relative to the first handle 70 to translate the second elongated member 40 relative to the first elongated member 20. In other embodiments, the second handle 80 may be rotated about the axis 130 relative to the first handle 70 to rotate the second elongated member 40 relative to the first elongated member 20. In further embodiments, the second handle 80 may be both translated and rotated relative to the first handle 70.
In the illustrated embodiments, the act of moving the first elongated member 20 and/or the second elongated member 40 to change a relative position between the first and second elongated members 20, 40 may be accomplished manually by hand(s). In other embodiments, the act of moving the first elongated member 20 and/or the second elongated member 40 to change a relative position between the first and second elongated members 20, 40 may be accomplished automatically and mechanically using a positioning device.
As shown in the figure, the device 10 includes one transducer 50. The transducer 50 may be a single focused piezoelectric element in some embodiments. The transducer 50 is located on the distal end 120 of the second elongated member 40. The transducer 50 is configured to deliver ultrasonic energy towards target tissue at the pancreas to treat tumor(s) at the pancreas. In some embodiments, the transducer 50 is configured to deliver sufficient acoustic energy to raise the temperature of targeted tissue to a temperature that is anywhere from 50° C. to 60° C. In other embodiments, the transducer 50 may be configured to deliver sufficient acoustic energy to raise the temperature of targeted tissue to a temperature higher than 60° C.
In the illustrated embodiments, the device 100 also includes a control (e.g., one or more buttons, knobs, switches, touch screen, etc.) 140 on the second handle 80 and an electrical wire 142. The electrical wire 142 is coupled to the control 140 and the transducer 50 for purpose of transmitting signal to activate the transducer 50 in response to actuation of control 140. In other embodiments, the device 10 may include multiple energy delivery components (e.g., multiple transducers 50). Also, in some embodiments, the control 140 may allow one or more operation parameters (e.g., power level, phase, activation duration, etc.) for the transducer(s) 50 be configured to adjust an amount of energy being delivered by one or more of the energy delivery components 50. In the illustrated embodiments, the transducer 50 is on one side of second elongated member 40. In other embodiments, the transducer 50 may extend circumferentially around the second elongated member 40. The second elongated member 40 may be translated, rotated, or both, to aim at target tissue.
In some embodiments, in addition to being able to deliver treatment energy, the transducer 50 may also be configured to deliver energy for imaging purpose. The imaging may be used for guidance of the device 10, and/or monitoring thermal tissue changes during or after treatment. In other embodiments, instead of using the transducer 50 in the transducer assembly for imaging purpose, the device 10 may include another transducer solely for imaging purpose. Such imaging transducer may be located next to or alongside (e.g., within 5 cm from) the transducer 50. Also, in some embodiments, the imaging transducer and the transducer 50 may be axially aligned along the longitudinal axis of the device 10. In other embodiments, the imaging transducer may be embedded in the transducer 50. In further embodiments, the imaging transducer may be located at a center of the transducer 50.
In other embodiments, the device 10 may include more than one transducer 50. For example, the transducers 50 may be arranged in the manners shown in
In other embodiments, instead of arranging the transducers 50 along the longitudinal axis 130, the transducers 50 may be arranged circumferentially around the longitudinal axis 130.
In other embodiments, instead of arranging the transducers 50 (example of energy delivery components) along the longitudinal axis 130 or circumferentially around the longitudinal axis 130, the transducers 50 may be arranged both along the axis 130 and around the axis 130 to form an array of energy delivery components.
In some embodiments, one or more of the transducers 50 in the embodiments of
A method of treating pancreatic cancer using the device 10 of
As shown in
As shown in
In the illustrated embodiments, the first elongated member 20 and second elongated member 40 are inserted together. In other embodiments, the first elongated member 20 may be inserted first, after which the second elongated member 40 is then inserted.
After the second elongated member 40 has been inserted, the handle 80 may be used to place the second elongated member 40 in a desired operative position which allows the transducer(s) 50 to deliver ultrasonic energy to the target area 200 at the pancreas 202. For example, the second elongated member 40 may be translated axially to align the transducer 50 with the target area 200 and/or rotated to face the transducer 50 towards the target area 200.
Next, as shown in
In some cases, if the device 10 has a single transducer 50, the single transducer 50 may be sufficient to cover the target area 200 at the pancreas 202 without further moving the transducer 50. In other cases, the transducer 50 may be further positioned (e.g., translated along, and/or rotated about, the longitudinal axis of the second elongated member 40) to thereby cover the entire target area 200. In some embodiments, the movement of the transducer 50 may be accomplished by moving the second elongated member 40 while energy is being delivered to thereby sweep the energy. Alternatively, the movement of the transducer 50 may be accomplished by moving the second elongated member 40 when the transducer 50 is not delivering any energy (e.g., between deliveries of energy).
In other embodiments in which multiple transducers 50 are provided at the device 10, the sweeping of the energy may not be required. For example, if there are multiple transducers 50 aligned along the axial length of the second elongated member 40 (like that shown in
As another example, if there are multiple transducers 50 disposed circumferentially around the longitudinal axis of the second elongated member 40 (like that shown in
In some embodiments, if the transducers 50 are arranged in an array configuration (like that shown in
In the illustrated example, the securing mechanism 30 is a balloon, which may also be used to couple ultrasonic energy to target area 200. When the transducer(s) 50 are activated, ultrasonic energy is emitted through the balloon 30 to treat target area 200 in the pancreas 202.
During the treatment process, the thermal imaging device 90 may be used to monitor the extent of heating of the target tissue and adjacent tissues. The purposes of the thermal imaging guidance are to assure complete ablation of targeted tumor tissue while minimizing damage to adjacent normal structures. In some embodiments, the thermal imaging device 90 may be configured to provide a map showing an extent of the heated areas. The map may be presented in different colors to show the different values of temperature at different locations. In some embodiments, the map may be displayed together with (e.g., superimposed over) an anatomy image, and may be presented to the user of the device 10 so that the user can see the extent of the heating relative to the anatomical features. In some embodiments, the user, from looking at the map, may determine that the target area 200 has not been sufficiently treated. This may occur, for example, when part(s) of the target area 200 has not received any energy from the transducer(s) 50, or when part(s) of the target area 200 has not received a sufficient amount of energy to kill off the tumor cells. In such cases, the user may reposition the transducer(s) 50, select another one of the transducer(s) 50 for activation, and/or change an operation parameter (e.g., power level, phase, etc.) for the transducer(s) 50, to thereby deliver energy to the untreated or under-treated areas.
After the procedure is completed, the fluid in the securing mechanism 30 is extracted to enable removal of the device 10 from the patient's body.
In other embodiments, the device 10 may have two balloons 30A and 30B (
In other embodiments, the device 10 may have a balloon dedicated for coupling ultrasonic energy. For example, in other embodiments, the device 10 may have an energy coupling balloon 400 for coupling ultrasonic energy from the transducer(s) 50 to the target area 200 at the pancreas 202 (
In one or more embodiments described herein, in which the device 10 includes an energy coupling balloon, fluid in such energy coupling balloon may be circulated to thereby provide a cooling effect during a treatment procedure. For example, as shown in
In the above embodiments, energy from the transducer(s) 50 is delivered through a wall of the stomach or the duodenum to reach target area at the pancreas. In other embodiments, energy from the transducer(s) 50 may be delivered from within the pancreas.
As discussed, the transducer(s) 50 in the device 10 of
Also, in some embodiments, the transducer(s) 50 inside the pancreas may be positioned by moving the second elongated member 40 to thereby aim an energy delivery path of the transducer(s) 50 towards a desired direction, as similarly discussed. For example, in some embodiments, the second elongated member 40 may be advanced distally or retracted proximally to thereby change the position of the transducer(s) 50 along an axis of the second elongated member 40. Alternatively, or additionally, the second elongated member 40 may also be rotated about its axis to turn the transducer(s) 50 so that they face a certain direction.
In other embodiments, instead of delivering ultrasonic energy, the component(s) 50 may be other types of energy delivery component(s). For example, in other embodiments, the energy delivery component(s) 50 at the device 10 of
In one or more embodiments described herein, the device 10 may optionally further include a delivery tube for housing the first elongated member 20 and the second elongated member 40.
As shown in
In the above embodiments, the device 10 has been described as having, or being used with, a thermal imaging device 90. In some embodiments, instead of a thermal imaging device, the component 90 may be a thermal couple or other temperature sensing device for monitoring the extent of heating at the target area. Also, in other embodiments, the component 90 may be other types of sensor configured to sense other characteristics associated with a heating of tissue. The component 90 may be a part of the device 10, or alternatively be used with the device 10.
In the above embodiments, the device 10 has been described as being configured/used to deliver ultrasonic energy to heat tissue(s). In other embodiments, the device 10 may be configured/used to apply ultrasonic energy for drug activation and targeting. For example, a drug may be consumed by a patient, or may be administered to within a patient (e.g., using a needle or IV). Then the device 10 may be inserted into the patient in the manner described herein, and may be operated to deliver ultrasonic energy to activate the drug inside the patient. In further embodiments, the device 10 may be configured/used to apply ultrasonic energy to generate hyperthermia at tissue within the patient. Thus, as the device 10 may be configured to perform thermal therapy. As used in this specification, the term “thermal therapy” is not limited to delivering/creating heat at tissue, and may refer to delivering/creating hyperthermia at tissue. Similarly, the term “ultrasonic energy” or “energy” is not limited to energy for creating heat (ablation), and may be energy for creating hyperthermia. In still further embodiments, the device 10 may be configured/used to apply ultrasonic energy to generate a biological/physiological effect, such as tissue remodeling. In other embodiments, the device 10 may be configured/used to apply ultrasonic energy to create mechanical effect(s) in target tissue(s). The energy can be delivered before, simultaneous, or after drug is infused or placed in the body.
Also, in other embodiments, instead of delivering ultrasonic energy, the component(s) 50 may be other types of energy delivery component(s). For example, in other embodiments, the energy delivery component(s) 50 at the device 10 of
Although particular embodiments have been shown and described, it will be understood that it is not intended to limit the claimed inventions to the preferred embodiments, and it will be obvious to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the claimed inventions. The specification and drawings are, accordingly, to be regarded in an illustrative rather than restrictive sense. The claimed inventions are intended to cover alternatives, modifications, and equivalents.
This application claims priority to and the benefit of U.S. Provisional Patent Application No. 61/812,126, filed on Apr. 15, 2013, the entire disclosure of which is expressly incorporated by reference herein.
This invention was made with Government support under contract NIH CA137472 and NIH CA 159992 awarded by National Institutes of Health. The Government has certain rights in this invention.
Number | Name | Date | Kind |
---|---|---|---|
4327738 | Green et al. | May 1982 | A |
4349032 | Koyata | Sep 1982 | A |
4817635 | Joines et al. | Apr 1989 | A |
5492126 | Hennige | Feb 1996 | A |
5558092 | Unger et al. | Sep 1996 | A |
5762066 | Law et al. | Jun 1998 | A |
6139819 | Unger et al. | Oct 2000 | A |
6231834 | Unger et al. | May 2001 | B1 |
6428504 | Riaziat et al. | Aug 2002 | B1 |
6521211 | Unger et al. | Feb 2003 | B1 |
6575969 | Rittman, III et al. | Jun 2003 | B1 |
6589174 | Chopra et al. | Jul 2003 | B1 |
6788977 | Fenn et al. | Sep 2004 | B2 |
7179449 | Lanza et al. | Feb 2007 | B2 |
7198778 | Achilefu et al. | Apr 2007 | B2 |
7220258 | Myhr | May 2007 | B2 |
7329402 | Unger et al. | Feb 2008 | B2 |
7452551 | Unger et al. | Nov 2008 | B1 |
7514069 | Achilefu et al. | Apr 2009 | B2 |
7771418 | Chopra et al. | Aug 2010 | B2 |
8108030 | Castella et al. | Jan 2012 | B2 |
8162834 | Feldman et al. | Apr 2012 | B2 |
20040002647 | Desai | Jan 2004 | A1 |
20040187876 | Myhr | Sep 2004 | A1 |
20040241095 | Achilefu et al. | Dec 2004 | A1 |
20060173442 | Dritschilo et al. | Aug 2006 | A1 |
20060182687 | Yang et al. | Aug 2006 | A1 |
20060293731 | Rubinsky et al. | Dec 2006 | A1 |
20070117133 | Trieu et al. | May 2007 | A1 |
20070167755 | Kolios et al. | Jul 2007 | A1 |
20070239062 | Chopra et al. | Oct 2007 | A1 |
20070255117 | Lanza et al. | Nov 2007 | A1 |
20070260138 | Feldman et al. | Nov 2007 | A1 |
20080015571 | Rubinsky et al. | Jan 2008 | A1 |
20080058316 | Eberhart et al. | Mar 2008 | A1 |
20080058788 | Boyden et al. | Mar 2008 | A1 |
20080154128 | Milner | Jun 2008 | A1 |
20080154344 | Trusty et al. | Jun 2008 | A1 |
20080177180 | Azhari et al. | Jul 2008 | A1 |
20090048546 | Appelman et al. | Feb 2009 | A1 |
20090069677 | Chen et al. | Mar 2009 | A1 |
20090143639 | Stark | Jun 2009 | A1 |
20090169478 | Leuschner et al. | Jul 2009 | A1 |
20090198131 | Fedewa et al. | Aug 2009 | A1 |
20090234225 | Martin et al. | Sep 2009 | A1 |
20090326359 | Hendriks et al. | Dec 2009 | A1 |
20100030190 | Singh | Feb 2010 | A1 |
20110034833 | Chopra et al. | Feb 2011 | A1 |
20110112400 | Emery | May 2011 | A1 |
20110257523 | Hastings | Oct 2011 | A1 |
20120027727 | Hall et al. | Feb 2012 | A1 |
20120034227 | Arlen et al. | Feb 2012 | A1 |
20120059018 | Park et al. | Mar 2012 | A1 |
20120101370 | Razzaque et al. | Apr 2012 | A1 |
20120150031 | Castella et al. | Jun 2012 | A1 |
20140052224 | Kassab | Feb 2014 | A1 |
20140163371 | Matsui | Jun 2014 | A1 |
Number | Date | Country |
---|---|---|
102122356 | Jul 2011 | CN |
1142606 | Oct 2001 | EP |
0831932 | May 2004 | EP |
1444991 | Aug 2004 | EP |
1021197 | Apr 2007 | EP |
1847294 | Oct 2007 | EP |
2283869 | Feb 2011 | EP |
2305214 | Apr 2011 | EP |
2311398 | Apr 2011 | EP |
1854508 | May 2011 | EP |
2394580 | Dec 2011 | EP |
WO8809152 | Dec 1988 | WO |
WO9221023 | Nov 1992 | WO |
WO9308876 | May 1993 | WO |
WO9405993 | Mar 1994 | WO |
WO9639079 | Dec 1996 | WO |
WO9640285 | Dec 1996 | WO |
WO9913919 | Mar 1999 | WO |
WO9955244 | Nov 1999 | WO |
WO 0045856 | Aug 2000 | WO |
WO 0103770 | Jan 2001 | WO |
WO 0113986 | Mar 2001 | WO |
WO 0236161 | May 2002 | WO |
WO 02060524 | Aug 2002 | WO |
WO 2004004709 | Jan 2004 | WO |
WO 2004017830 | Mar 2004 | WO |
WO 2004026098 | Apr 2004 | WO |
WO 2004026098 | Apr 2004 | WO |
WO 2004035110 | Apr 2004 | WO |
WO 2004064914 | Aug 2004 | WO |
WO 2005002671 | Jan 2005 | WO |
WO 2005089813 | Sep 2005 | WO |
WO 2006018837 | Feb 2006 | WO |
WO 2006042186 | Apr 2006 | WO |
WO 2006074272 | Jul 2006 | WO |
WO 2007001747 | Jan 2007 | WO |
WO 2007008700 | Jan 2007 | WO |
WO 2007124458 | Jan 2007 | WO |
WO 2007021621 | Feb 2007 | WO |
WO 2007030571 | Mar 2007 | WO |
WO 2007100895 | Sep 2007 | WO |
WO 2007117572 | Oct 2007 | WO |
WO 2007124458 | Nov 2007 | WO |
WO 2008007355 | Jan 2008 | WO |
WO 2008015599 | Feb 2008 | WO |
WO 2008067079 | Jun 2008 | WO |
WO 2008086219 | Jul 2008 | WO |
WO 2009002492 | Dec 2008 | WO |
WO 2009029215 | Mar 2009 | WO |
WO 2009032949 | Mar 2009 | WO |
WO 2009041910 | Apr 2009 | WO |
WO 2009041912 | Apr 2009 | WO |
WO 2009042637 | Apr 2009 | WO |
WO 2009045478 | Apr 2009 | WO |
WO 2009052481 | Apr 2009 | WO |
WO 2009103741 | Aug 2009 | WO |
WO 2009111273 | Sep 2009 | WO |
WO 2009154963 | Dec 2009 | WO |
WO 2010118387 | Oct 2010 | WO |
WO 2011028698 | Mar 2011 | WO |
WO 2011033390 | Mar 2011 | WO |
WO 2011073725 | Jun 2011 | WO |
WO 2011102904 | Aug 2011 | WO |
WO 2011102905 | Aug 2011 | WO |
WO 2011102906 | Aug 2011 | WO |
WO 2011137114 | Nov 2011 | WO |
WO 2011137441 | Nov 2011 | WO |
WO 2012007567 | Jan 2012 | WO |
WO 2012009703 | Jan 2012 | WO |
WO 2012012750 | Jan 2012 | WO |
WO 2012033901 | Mar 2012 | WO |
WO 2012047582 | Apr 2012 | WO |
Entry |
---|
Elmar M. Merkle, et al, “MR Imaging-guided Radio-frequency Thermal Ablation in the Pancreas in a Porcine Model with a Modified Clinical C-Arm System1”, Nov. 1999. |
Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy, http://www.bioportfolio.com/resources/trial/88203/Correlation-Of-Mr-Thermal-Imaging-To-Actual-Size-Of-Ablation-During-Laser.html, May 2008. |
Number | Date | Country | |
---|---|---|---|
20150018725 A1 | Jan 2015 | US |
Number | Date | Country | |
---|---|---|---|
61812126 | Apr 2013 | US |